Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Free Cash Flow (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Free Cash Flow for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 13.76% year-over-year to $2.2 million, compared with a TTM value of -$4.8 million through Dec 2025, down 119.11%, and an annual FY2025 reading of -$4.8 million, down 119.11% over the prior year.
  • Free Cash Flow was $2.2 million for Q4 2025 at Cytek Biosciences, up from -$4.6 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $14.7 million in Q3 2024 and bottomed at -$8.9 million in Q2 2022.
  • Average Free Cash Flow over 5 years is $407250.0, with a median of $226000.0 recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 356.35% in 2022, then soared 442.44% in 2024.
  • Year by year, Free Cash Flow stood at $5.3 million in 2021, then plummeted by 162.48% to -$3.3 million in 2022, then soared by 388.19% to $9.6 million in 2023, then plummeted by 79.94% to $1.9 million in 2024, then grew by 13.76% to $2.2 million in 2025.
  • Business Quant data shows Free Cash Flow for CTKB at $2.2 million in Q4 2025, -$4.6 million in Q3 2025, and -$1.5 million in Q2 2025.